GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Capex-to-Operating-Income

Abionyx Pharma (XPAR:ABNX) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Abionyx Pharma's Capital Expenditure for the six months ended in Dec. 2023 was €-0.06 Mil. Its Operating Income for the six months ended in Dec. 2023 was €-1.06 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Abionyx Pharma Capex-to-Operating-Income Historical Data

The historical data trend for Abionyx Pharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Capex-to-Operating-Income Chart

Abionyx Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abionyx Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abionyx Pharma's Capex-to-Operating-Income

For the Biotechnology subindustry, Abionyx Pharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abionyx Pharma's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's Capex-to-Operating-Income falls into.



Abionyx Pharma Capex-to-Operating-Income Calculation

Abionyx Pharma's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.13) / -3.165
=N/A

Abionyx Pharma's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.059) / -1.06
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abionyx Pharma  (XPAR:ABNX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Abionyx Pharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Abionyx Pharma (XPAR:ABNX) Business Description

Traded in Other Exchanges
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines